OptimizeRx has announced a finance leadership transition reflecting disciplined succession planning. The Board has appointed Andy D'Silva to succeed Ed Stelmakh as Chief Financial Officer, effective January 1, 2027, and Heather Favazza as Chief Accounting Officer, also effective January 1, 2027.
Andy D'Silva appointed CFO and Heather Favazza CAO effective January 1, 2027.
Current CFO Ed Stelmakh transitions to Strategic Advisor through 2027.
D'Silva previously served as Chief Business Officer at OptimizeRx.
Favazza has been Corporate Controller for eight years.
Stelmakh led transformation including Medicx acquisition and debt refinancing.
OptimizeRx provides healthcare technology for life sciences engagement.
Over the past five years, Stelmakh helped transform OptimizeRx's financial foundation and position the Company for its next phase of growth. Under his leadership, the Company significantly expanded gross and operating margins, strengthened operating discipline, refinanced its debt, completed the acquisition and successful integration of Medicx, streamlined the portfolio through divestiture of non-core assets, and built a high-performing finance and strategy organization. To enable a seamless leadership changeover, Stelmakh will continue serving as Chief Financial & Strategy Officer through December 31, 2026, working closely with D'Silva and Favazza to ensure an orderly transfer of responsibilities.
D'Silva has most recently served as Chief Business Officer and has worked closely with the executive leadership team and the Board on the Company's financial strategy, capital allocation, investor relations, corporate development, and long-range planning. Favazza has been the Company's Corporate Controller for the past eight years and has consistently demonstrated strong leadership, technical expertise, and commitment to excellence, strengthening accounting operations, financial reporting, internal controls, and compliance.
"Ed has been an exceptional partner to me, our Board, and our executive leadership team," said Silvestro. "His guidance has strengthened our financial foundation, sharpened our strategic execution, and helped build an outstanding finance organization. Perhaps his most enduring contribution is the talented team he has developed, which gives us confidence in this leadership change."
"Andy has most recently served as Chief Business Officer and has worked closely with the executive leadership team and the Board on the Company's financial strategy, capital allocation, investor relations, corporate development, and long-range planning," said Silvestro. "His work has been vital to the strong financial foundation we have established, which makes him well-positioned to step into this new role."
"Heather has been the Company's Corporate Controller for the past eight years and has consistently demonstrated strong leadership, technical expertise, and an unwavering commitment to excellence," Silvestro added. "She has been instrumental in strengthening accounting operations, financial reporting, internal controls, compliance, and the Company's finance infrastructure and is well prepared to serve as our Chief Accounting Officer."
About OptimizeRx
OptimizeRx is a leading healthcare technology company redefining how life science brands connect with patients and healthcare providers. The platform combines innovative AI-driven tools like Dynamic Audience Activation Platform and Micro-Neighborhood Targeting to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
